The HRT misuse and osteoporosis epidemic: A possible future scenario

Climacteric

Volumn 10, Issue 4, 2007, Pages 273-275

  Gambacciani, M ^a   Ciaponi, M ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Hormone replacement therapy; Osteoporosis

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; COGNITION; EPIDEMIC; FRACTURE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION;

DATA INTERPRETATION, STATISTICAL; DISEASE OUTBREAKS; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; MASS MEDIA; OSTEOPOROSIS, POSTMENOPAUSAL; PUBLIC OPINION; RANDOMIZED CONTROLLED TRIALS; WOMEN'S HEALTH;

EID: 34547200640     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701511277     Document Type: Article

References (25)

1. CDC/NCHS: NHANES III - HRT. Factors associated with HRT use. NHI, Office of Research of Women's Health, March 2001
2. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
3. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
4. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53
5. Genazzani AR, Gambacciani M, Schneider HP, Christiansen C; International Menopause Society Expert Workshop. Postmenopausal osteoporosis: therapeutic options. Climacteric 2005;8:99-109
6. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
7. Anderson GL, Limacher M, Assaf A, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12
8. Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporosis Int 2001;12:251-8
9. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-76
10. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-51
11. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-35
12. Kanis JA, Oden A, Johnel O, Jonsson B, de Laette C, Dawson A. The burden of osteoporotic fractures. A method for setting intervention thresholds. Ostoeporosis Int 2001;12:417-27
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45
14. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82
15. McClung MR, Geusens P, Millar PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
16. Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecol Endocrinol 2002;16:255-7
17. Gambacciani M, Genazzani AR. The osteoporosis dilemma. Gynecol Endocrinol 2004;18:59-61
18. Genazzani AR, Gambacciani M, Simoncini T. Estrogens and women's health: a scary or a fairy tale? Gynecol Endocrinol 2004;18:175-8
19. Gambacciani M, Genazzani AR. The Xmas present for women's health: a strike to osteoporosis prevention. Maturitas 2004;48:9-11
20. Naftolin F, Schneider HP, Sturdee DW, et al. Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:333-7
21. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C, for the PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-17
22. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Hlth 2006;1:35-44
23. Hsia J, Lange RD, Kuller L, et al., for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006;166:357-65
24. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
25. Stefanick ML, Anderson GL, Margolis KL, et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57